Zheng W J, Zhang N, Zhu X C, Chi S S, Zhang W, Wei W, Zhao Y, Dong Y
Department of Rheumatology and Clinical Immunology, Peking Union Medical College, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.
Department of Rheumatology and Clinical Immunology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Zhonghua Nei Ke Za Zhi. 2021 Oct 1;60(10):860-867. doi: 10.3760/cma.j.cn112138-20210604-00398.
Behçet's syndrome (BS) is classified among variable vessel vasculitis with unknown etiology and extensively heterogeneous clinical features. It is easily missed or misdiagnosed due to the lack of a specific laboratory diagnosis index. Based on the evidence and guidelines from China and other countries, the Chinese Rheumatology Association developed the standardization of diagnosis and treatment of BS. The purposes are: (1) To standardize the detection and interpretation of key indicators for BS; (2) To standardize rational management for BS patients with topical and systemic organ involvement to reduce complications and improve outcomes.
白塞病（BS）被归类为病因不明的可变血管性血管炎，具有广泛的异质性临床特征。由于缺乏特异性实验室诊断指标，该病很容易被漏诊或误诊。基于中国和其他国家的证据及指南，中华医学会风湿病学分会制定了白塞病的诊断和治疗规范。目的如下：（1）规范白塞病关键指标的检测及解读；（2）规范白塞病局部和全身器官受累患者的合理管理，以减少并发症并改善预后。
